It has been developed by Forchronic and is being tested in patients with chemotherapy with positive results
Forchronic has developed a new bioactive compound from supercritical extract of rosemary high content on earthlings which is showing positive results in chemotherapy treatments for colon cancer.
This precision nutritional supplement inhibits metabolic pathways associated with tumor growth and reinforces the patient's immune system so it has a preventive effect. It improves the reception and effectiveness of certain anti-tumoral treatments such as the use of fluoropiamines, one of the most widely used therapies against colon cancer. Colorectal is the most diagnosed cancer in the Spanish population (14% of the total with 37.172 cases detected in 2018) and the second in mortality with 15,656 deaths per year (14% of those produced by cancer). (See photo)
The bioactive compound is vehiculized through a lipidic system also developed by Forchronic that improves absorption speed by digestion. As Enrique Sainz, CEO of the company says: “The lipidic vehicle or carrier radically increases the bioavailability and bioactivity of the compound by providing high efficiency.”
The Forchronic research team consists of members of the bioactive lipid team of the Autonomous University of Madrid, the molecular oncology group of the IMDEA Food Institute and the Oncology Service of the Infanta Sofia Hospital. It is currently testing the formula in patients with colon cancer who receive the aforementioned antitumoral treatment with positive results. The new product is a metabolic path inhibitor associated with tumor growth and has a preventive effect by strengthening the patient's immune system. The effects achieved with this formula are confirmed during previous animal trials. Horoscopos y tarot de amor
Lung cancer and autoimmune diseases
Forchronic is also in the process of verifying the validity of its bioactive compound for the treatment of tumors associated with lung cancer and has recently obtained approval to begin trials in people affected by this pathology.
Also Dr. Guillermo Reglero, professor at the UAM, Director of the IMDEA Food and founder of Forchronic SL, recalls: “the current results open paths to other applications, not only cancer, but also immune system-related diseases.” The compound has a clear protective effect of the immune system so trials should be completed to know its possibilities in autoimmune diseases such as rheumatoid arthritis, type I diabetes, psoriasis, celiac disease and multiple sclerosis. Forchronic previews the entry into clinical trials to validate the therapeutic capacity of its bioactive formula in some of these pathologies soon.
After eight years of research the formula has recently received the concession as a European patent and Forchronic estimates that it can be marketed from 2020. Several companies in the pharmaceutical sector and clinical nutrition have already been interested in a possible agreement.
Forchronic is a company promoted by the investment society CanaanResearch and Investment, the Autonomous University of Madrid, the IMDEA Food Institute and the Infanta Sofia University Hospital. Its objective is research in Precision Nutrition for the development of nutraceuticals that allow personalization in the treatment of the patient from a genetic and physiological point of view to achieve maximum effectiveness.
Canaan Research and Investment
Canaan Research and Investment is an investment society Venture Capital created for the realization and management of investment processes in companies, patents and research lines. Canaan's team is composed of technological managers, scientific experts and financial analysts with an extensive career in management, direction and development in R & D+i projects.
A formula with rosemary extract combats colon cancer
It has been developed by Forchronic and is being tested in patients with chemotherapy with positive results /COMUNICAE/ /COMUNICAE/
Acording with the Digital Millennium Copyright Act (“DMCA”), Pub. L. 105-304 If you believe that your copyrighted work is being infringed, notify our team at the email [email protected]